News & Updates
Filter by Specialty:
Empagliflozin improves outcomes in HFpEF patients regardless of age
Treatment with empagliflozin results in a reduction in heart failure (HF) risk and renal outcomes and in better health-related quality of life (HRQoL) among patients with chronic HF with preserved ejection fraction (HFpEF), a study has shown. In addition, the study drug is well tolerated by older patients.
Empagliflozin improves outcomes in HFpEF patients regardless of age
06 Jul 2022
Vedolizumab appears safe, effective in first-line treatment of ulcerative colitis in children
Children with ulcerative colitis seem to respond well to vedolizumab in the first-line setting, inducing remission without increasing the risk of adverse events, according to a small study.
Vedolizumab appears safe, effective in first-line treatment of ulcerative colitis in children
06 Jul 2022
Chlorhexidine a safe, reasonable option for vaginal antisepsis
Vaginal antisepsis with chlorhexidine proves noninferior to that with iodine in terms of the incidence of gynaecologic surgery-associated urinary tract infection and vaginal irritation, as reported in a study.
Chlorhexidine a safe, reasonable option for vaginal antisepsis
06 Jul 2022
PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
In hepatocellular carcinoma (HCC), poly(ADP-ribose) glycohydrolase (PARG) may serve as an oncogene by modulating PARG/DDB1/c-Myc signaling and be used as a biomarker to identify HCC patients who may derive benefit from anti-PD-1 treatment, suggests a study.
PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
05 Jul 2022
Concurrent DOAC, tamoxifen use poses no elevated bleeding risk
In breast cancer patients receiving direct oral anticoagulants (DOACs), tamoxifen is safe to use and does not increase the risk of haemorrhage as compared with concurrent use of an aromatase inhibitor (AI), a study has found.
